Eagle Pharmaceuticals, Inc. (EGRX) Stock Rating Lowered by BidaskClub

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Other analysts also recently issued research reports about the stock. Mizuho lowered their target price on shares of Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating for the company in a report on Thursday, May 25th. Piper Jaffray Companies set a $118.00 price target on shares of Eagle Pharmaceuticals and gave the company an “overweight” rating in a research report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. Royal Bank Of Canada set a $86.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, April 24th. Finally, ValuEngine upgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $90.00.

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) traded down 1.08% during midday trading on Friday, hitting $75.73. 310,556 shares of the company were exchanged. The firm’s 50 day moving average price is $77.28 and its 200 day moving average price is $77.94. Eagle Pharmaceuticals has a one year low of $42.33 and a one year high of $97.15. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 11.90 and a beta of 1.48.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.44 by $0.02. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The business had revenue of $76.80 million for the quarter, compared to analyst estimates of $70.10 million. During the same quarter in the previous year, the company posted ($0.06) EPS. The business’s quarterly revenue was up 159.5% on a year-over-year basis. Analysts forecast that Eagle Pharmaceuticals will post $3.66 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Stock Rating Lowered by BidaskClub” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/07/16/eagle-pharmaceuticals-inc-egrx-stock-rating-lowered-by-bidaskclub.html.

In related news, CFO Pete A. Meyers purchased 350 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The stock was bought at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the transaction, the chief financial officer now owns 350 shares in the company, valued at $25,021.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Proquest Investments Iv, L.P. sold 54,180 shares of the stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $88.38, for a total transaction of $4,788,428.40. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 805 shares of company stock valued at $61,790. 19.50% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in Eagle Pharmaceuticals during the fourth quarter valued at $1,935,000. State Board of Administration of Florida Retirement System raised its position in Eagle Pharmaceuticals by 2.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 5,305 shares of the specialty pharmaceutical company’s stock valued at $421,000 after buying an additional 150 shares during the last quarter. Comerica Bank raised its position in Eagle Pharmaceuticals by 5.2% in the fourth quarter. Comerica Bank now owns 8,445 shares of the specialty pharmaceutical company’s stock valued at $585,000 after buying an additional 415 shares during the last quarter. FMR LLC acquired a new position in shares of Eagle Pharmaceuticals during the fourth quarter worth $7,300,000. Finally, New York State Teachers Retirement System raised its position in shares of Eagle Pharmaceuticals by 2.0% in the fourth quarter. New York State Teachers Retirement System now owns 9,957 shares of the specialty pharmaceutical company’s stock worth $790,000 after buying an additional 200 shares in the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply